AzTrials
AzTrials

Post-acne ErythemaNCT06998589

Comparison of the Efficacy and Safety of Delicate Pulsed Light and Q-Switched 1064 nm Nd:YAG Laser in the Treatment of Post-Acne Erythema

A study testing DPL in people with Post-acne Erythema, run by Second Affiliated Hospital of Xi'an Jiaotong University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Acne vulgaris is a common chronic dermatological condition, affecting approximately 85% of adolescents worldwide and ranking eighth among all chronic diseases. Its exacerbation is often associated with recurrent lesions, inadequate treatment, and poor skincare habits such as squeezing or scratching, which frequently… Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Post-acne Erythema
What is being tested?
DPL
Could I receive a placebo?
No, everyone receives an active treatment
How many people
26 participants
Where
1 siteChina
Study dates
17 Jan 2025to 20 May 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Age between 18 and 60 years, regardless of gender;
  • Clinically and dermatoscopically diagnosed with acne and post-acne erythema (PAE) with bilaterally symmetrical facial lesions;
  • Patients with normal cognitive function and stable mental status;
  • Patients with good communication abilities;
  • Voluntary participation in the study with signed informed consent.

Who cannot join

  • Patients meeting any of the following conditions will be excluded from the study:
  • History of photosensitivity;
  • Presence of severe immunological disorders;
  • Keloid or hypertrophic scarring tendency;
  • Pregnant or breastfeeding individuals;
  • Alcohol abuse;
Show all 11Show fewer
  • Presence of other facial skin diseases;
  • Mental illness or psychiatric disorders that impair compliance;
  • Currently pregnant or lactating;
  • Presence of severe internal medical conditions;
  • Poor treatment compliance or inability to cooperate due to psychiatric conditions.

Trial locations and contacts

1 site in 1 country.

China1 site
  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, 710004

Other trials in China

About this study

Acne vulgaris is a common chronic dermatological condition, affecting approximately 85% of adolescents worldwide and ranking eighth among all chronic diseases. Its exacerbation is often associated with recurrent lesions, inadequate treatment, and poor skincare habits such as squeezing or scratching, which frequently lead to the development of post-acne erythema (PAE). PAE is a vascular lesion located beneath the surface of the skin, characterized by a red appearance due to the clustering of dilated capillaries. Although PAE typically improves within 2 to 6 months, it may persist longer in some cases and even result in post-inflammatory hyperpigmentation. This is particularly prevalent in individuals with darker skin tones, where the incidence of PAE and hyperpigmentation ranges from approximately 45.5% to 87.2%. Facial acne not only affects physical appearance but also significantly impairs social interactions and can lead to psychological distress, including low self-esteem and depression.

Low-energy, large-spot 1064 nm Nd:YAG laser, which belongs to the near-infrared spectrum, has deeper skin penetration and can effectively target deeper dermal tissues. In the treatment of PAE, the laser energy is absorbed by dilated microvasculature in the skin, promoting vasoconstriction and reducing localized redness and swelling. The low energy setting minimizes thermal damage while stimulating collagen production, thereby enhancing skin repair and improving the appearance of erythema.

Read more

Delicate Pulsed Light (DPL) operates by emitting pulses of light at specific wavelengths that selectively target skin chromophores. In treating PAE, DPL precisely controls the wavelength and pulse intensity to target dilated blood vessels, thereby alleviating redness and inflammation. Additionally, DPL stimulates the skin's natural repair mechanisms and promotes collagen synthesis, accelerating the resolution of erythema and enhancing overall skin texture. Compared with conventional Intense Pulsed Light (IPL), DPL offers more accurate light modulation, fewer side effects, and better adaptability to various skin types and conditions.

In this study, we conducted a split-face randomized controlled trial to compare the clinical efficacy and safety of low-energy large-spot 1064 nm Nd:YAG laser and DPL in treating acne and PAE. We aimed to explore whether there are significant differences between these two modalities in terms of clinical outcomes for post-acne erythema.

Read the detailed description

Acne vulgaris is a highly prevalent chronic inflammatory skin disease, affecting approximately 85% of adolescents globally, and ranking eighth among all chronic conditions in terms of global disease burden. Although traditionally perceived as a benign and self-limiting disorder, its impact on quality of life, especially when accompanied by persistent post-lesional sequelae such as post-acne erythema (PAE), is increasingly recognized. The aggravation of acne is often multifactorial, closely linked to recurrent inflammatory episodes, inadequate therapeutic interventions, and improper skincare behaviors such as manual squeezing or scratching of lesions. These factors not only exacerbate active lesions but also contribute significantly to the development and persistence of PAE.

PAE is a vascular response resulting from the dilation and proliferation of superficial dermal capillaries following inflammatory acne lesions. It presents clinically as well-demarcated erythematous macules or patches, primarily located on previously inflamed sites. Although PAE can spontaneously resolve within 2 to 6 months, in many individuals-particularly those with darker Fitzpatrick skin types-it may persist significantly longer, often overlapping with post-inflammatory hyperpigmentation (PIH). Epidemiological data suggest that the incidence of PAE and PIH in darker-skinned populations ranges from 45.5% to as high as 87.2%, highlighting the need for effective interventions. Given that acne and its sequelae predominantly involve facial skin, the psychosocial burden is substantial. Patients often experience reduced self-esteem, social withdrawal, and even symptoms of anxiety and depression, underscoring the importance of timely and effective treatment strategies.

Among current therapeutic approaches, low-energy, large-spot 1064 nm Q-switched Nd:YAG laser has garnered attention due to its favorable safety profile and ability to penetrate deeper dermal layers. Operating in the near-infrared spectrum, the 1064 nm wavelength is selectively absorbed by hemoglobin in dilated capillaries, promoting vasoconstriction and diminishing visible erythema. At low energy densities, this laser minimizes thermal injury to surrounding tissues while simultaneously stimulating neocollagenesis, thereby contributing to both vascular remodeling and dermal regeneration. This dual mechanism supports its utility in managing PAE with minimal downtime.

In contrast, Delicate Pulsed Light (DPL), an advanced form of filtered intense pulsed light (IPL), offers enhanced precision through narrower wavelength bands, typically within the 500-650 nm range. This allows for more selective targeting of hemoglobin and melanin, improving therapeutic outcomes while reducing the risk of non-specific tissue damage. In the context of PAE, DPL effectively targets superficial vascular lesions, mitigates inflammatory processes, and promotes skin healing through controlled photothermal effects and collagen stimulation. Compared to conventional IPL, DPL provides improved treatment accuracy, reduced adverse effects, and better adaptability across a range of skin phototypes.

Given the growing demand for non-invasive, effective, and safe interventions for PAE, comparative studies on commonly used energy-based devices are warranted. Therefore, in this study, we conducted a prospective, split-face, randomized controlled trial to compare the clinical efficacy and safety of low-energy 1064 nm Nd:YAG laser and DPL in the treatment of acne and PAE. This design allows for intra-individual comparison, thereby minimizing confounding variables and enhancing the validity of outcome assessments. Our primary objective was to determine whether there are significant differences in the therapeutic outcomes between these two modalities, with a particular focus on erythema resolution, patient satisfaction, and adverse event profiles.

Being tested
DPL
Keywords
post-acne erythema

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DPLOther

    The DPL treatment was randomly applied to one side of the face, with an energy density of 6-8 J/cm². Sessions were performed at intervals of 2-3 weeks, for a total of six treatments..The randomly assigned half of the face received large-spot, low-energy 1064 nm laser treatment at an energy density of 0.8-1 J/cm², performed at intervals of 2-3 weeks for a total of six sessions.

Study groups in NCT06998589
Study groupRoleWhat they receive
DPLExperimentalThe DPL treatment was randomly applied to one side of the face, with an energy density of 6-8 J/cm². Sessions were performed at intervals of 2-3 weeks, for a total of six treatments.
Receives: Other: DPL
Q-switched 1064 nm Nd:YAG laserExperimentalThe randomly assigned half of the face received large-spot, low-energy 1064 nm laser treatment at an energy density of 0.8-1 J/cm², performed at intervals of 2-3 weeks for a total of six sessions.
Receives: Other: DPL

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. PAE lesion count

    The post-acne erythema (PAE) lesion count is an important objective indicator for assessing the severity of PAE. It involves recording the number of erythematous lesions on the face to evaluate changes before and after treatment. A higher lesion count indicates more severe erythema and poorer skin recovery. The assessment is typically conducted independently by two trained dermatologists under standardized lighting conditions, with high-resolution imaging systems used when necessary to enhance accuracy and consistency. Care is taken to distinguish PAE from other cutaneous manifestations such as active acne, post-inflammatory hyperpigmentation, and scarring. As a quantitative measure of erythema severity and improvement, the lesion count is widely applied in clinical studies involving light-based and laser therapies.

    Measured: 0, 4, 8, 12 weeks

Secondary outcomes (3)
  1. CEA score

    The CEA score can be used to estimate the overall severity of the patient's condition. The score ranges from 0 to 4, with higher scores indicating more severe conditions.

    Measured: 0, 4, 8, 12 weeks

  2. erythema index

    Use non-invasive skin analyzer to measure the erythema index on the patient's facial skin at each follow-up visit.The larger the value, the more severe the erythema.

    Measured: 0, 4, 8, 12 weeks

  3. GFSS score

    The name of the scale is Global Flushing Severity Scale. The score ranges from 0 to 4, with higher scores indicating more severe conditions.

    Measured: 0, 4, 8, 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 May 2025
  2. Study start17 Jan 2025
  3. Primary completion20 May 2025
  4. Study completion20 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
26 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06998589
Sponsor's protocol ID
2025086
Status last verified
May 2025
First submitted
17 May 2025
Last updated
31 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Wu X, Wang X, Wu X, Cen Q, Xi W, Shang Y, Zhang Z, Lin X. Intense Pulsed Light Therapy Improves Acne-Induced Post-inflammatory Erythema and Hyperpigmentation: A Retrospective Study in Chinese Patients. Dermatol Ther (Heidelb). 2022 May;12(5):1147-1156. doi: 10.1007/s13555-022-00719-9. Epub 2022 Apr 12.

    PubMed 35415801
  • Urban K, Chu S, Giesey RL, Mehrmal S, Uppal P, Delost ME, Delost GR. Burden of skin disease and associated socioeconomic status in Asia: A cross-sectional analysis from the Global Burden of Disease Study 1990-2017. JAAD Int. 2020 Dec 10;2:40-50. doi: 10.1016/j.jdin.2020.10.006. eCollection 2021 Mar.

    PubMed 34409353

Questions about this trial

What is this clinical trial studying?

A study testing DPL in people with Post-acne Erythema, run by Second Affiliated Hospital of Xi'an Jiaotong University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

PAE lesion count (time frame: 0, 4, 8, 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06998589, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in